Citation Tools
E-Poster viewings
Trials in Progress
IGCS19-0383
393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer